Products
Paridiprubart Biosimilar Monoclonal Antibody (TLR4) for Research
Cat No.: GMP-Bios-INN-1328
Anti-TLR4/CD284 therapeutic antibody (Pre-made Paridiprubart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Paridiprubart (development code EB05) is a monoclonal antibody targeting Toll-like receptor 4 (TLR4). It is developed by Edesa Biotech for COVID-19. It is in Phase III clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1328-1mg | 1mg | 3090 |
| GMP-Bios-INN-1328-10mg | 10mg | |
| GMP-Bios-INN-1328-100mg | 100mg | |
| GMP-Bios-INN-1328-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Paridiprubart biosimilar, Whole mAb, Anti-TLR4/CD284 Antibody: Anti-TLR4/CD284/Toll-like receptor 4/hToll therapeutic antibody |
| INN Name | Paridiprubart |
| Target | TLR4/CD284 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | 4r7d:AB:CD:EF:GH:IJ:MN:OP |
| 99% SI Structure | None |
| 95-98% SI Structure | 4r7n:AB:CD:EF:GH:IJ:MN:OP:QR:ST |
| Year Proposed | 2022 |
| Year Recommended | 2022 |
| Companies | Edesa Biotech |
| Conditions Approved | na |
| Conditions Active | COVID-19 |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
